Your browser is no longer supported. Please, upgrade your browser.
MRTX Mirati Therapeutics, Inc. daily Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.69 Insider Own4.80% Shs Outstand42.69M Perf Week-12.50%
Market Cap3.61B Forward P/E- EPS next Y-5.91 Insider Trans1.85% Shs Float38.80M Perf Month-6.98%
Income-169.20M PEG- EPS next Q-1.44 Inst Own99.10% Short Float12.71% Perf Quarter-4.94%
Sales6.30M P/S573.47 EPS this Y-14.40% Inst Trans-2.93% Short Ratio8.90 Perf Half Y1.54%
Book/sh11.08 P/B7.64 EPS next Y-12.60% ROA-44.80% Target Price115.93 Perf Year11.37%
Cash/sh10.64 P/C7.95 EPS next 5Y- ROE-48.60% 52W Range55.11 - 132.59 Perf YTD-34.32%
Dividend- P/FCF- EPS past 5Y7.80% ROI- 52W High-33.52% Beta2.29
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low59.95% ATR4.42
Employees63 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)36.86 Volatility5.39% 4.45%
OptionableYes Debt/Eq0.00 EPS Q/Q-62.80% Profit Margin- Rel Volume0.71 Prev Close84.63
ShortableYes LT Debt/Eq0.00 EarningsMar 05 BMO Payout- Avg Volume553.89K Price88.15
Recom2.00 SMA20-3.98% SMA50-13.46% SMA200-5.98% Volume366,038 Change4.16%
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Sep-24-19Upgrade Guggenheim Neutral → Buy $116
Sep-09-19Upgrade Jefferies Hold → Buy $89 → $105
Aug-02-19Downgrade JP Morgan Neutral → Underweight $85
Jul-18-19Initiated Deutsche Bank Hold $86
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jun-04-19Upgrade Citigroup Neutral → Buy $76 → $132
Apr-17-19Initiated JP Morgan Neutral $72
Mar-25-19Initiated Credit Suisse Outperform $85
Mar-04-19Downgrade Citigroup Buy → Neutral $64 → $77
Feb-15-19Initiated Piper Jaffray Overweight $85
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-29-18Upgrade Guggenheim Neutral → Buy
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Mar-12-18Initiated Barclays Overweight $44
Jan-09-18Reiterated H.C. Wainwright Buy $17 → $21
Nov-14-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-25-20 08:00AM  Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates PR Newswire
Feb-19-20 10:35AM  Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs GuruFocus.com
08:30AM  Mirati Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-15-20 11:30AM  Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium PR Newswire
Jan-14-20 04:01PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jan-09-20 10:00PM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire -6.01%
08:39AM  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results Benzinga
Jan-08-20 04:03PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Jan-07-20 07:57AM  The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering Benzinga -10.11%
Jan-06-20 04:30PM  Mirati Therapeutics Announces Executive Management Changes PR Newswire
Jan-03-20 01:36PM  Here's What We Think About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay Simply Wall St.
Jan-02-20 04:30PM  Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference PR Newswire -9.82%
Dec-26-19 11:11AM  2019 Review: Most Favored Hedge Fund Stocks vs. Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Dec-19-19 10:09AM  4 Drug/Biotech Outperformers That May Lose Steam in 2020 Zacks
Dec-18-19 08:40AM  Options Traders Expect Huge Moves in Mirati (MRTX) Stock Zacks
Dec-13-19 07:00AM  BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019 GlobeNewswire +5.78%
Dec-04-19 08:35PM  Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Nov-09-19 06:15PM  Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting PR Newswire
Nov-04-19 06:55PM  Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM  Mirati Therapeutics Reports Third Quarter 2019 Financial Results PR Newswire
Nov-03-19 07:10AM  The Mirati Therapeutics (NASDAQ:MRTX) Share Price Gained 1921% And Shareholders Are Jubilant Simply Wall St.
Oct-29-19 07:32AM  The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga +16.73%
Oct-28-19 04:15PM  Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics PR Newswire
04:15PM  Mirati drug shrinks tumors in some cancer patients in early-stage trial Reuters
Oct-25-19 11:05AM  Mirati Therapeutics, Inc. (MRTX): Are Hedge Funds Right About This Stock? Insider Monkey +6.10%
Oct-23-19 04:45PM  Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting PR Newswire
Oct-17-19 09:00AM  Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics PR Newswire +8.35%
Oct-16-19 04:22PM  Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts Benzinga
Oct-07-19 06:00AM  After 500% Surge, Miratis Day of Reckoning Is Approaching Bloomberg
Oct-01-19 09:09AM  Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock? Zacks -8.87%
Sep-28-19 08:34AM  Here's Why We're Not Too Worried About Mirati Therapeutics's (NASDAQ:MRTX) Cash Burn Situation Simply Wall St.
Sep-09-19 10:10AM  Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Zacks -5.24%
Sep-05-19 09:16PM  4 Biotech Stocks With Big Catalysts in September Motley Fool
Sep-04-19 09:15AM  Amgens White Whale Cancer Data May Send Shares to Record High Bloomberg
Aug-23-19 10:15PM  Mirati Therapeutics Inc (MRTX) President & CEO Charles M Baum Sold $4.5 million of Shares GuruFocus.com
09:38AM  A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX) Simply Wall St.
Aug-15-19 04:30PM  Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources PR Newswire
Aug-05-19 04:15PM  Mirati Therapeutics Reports Second Quarter 2019 Financial Results PR Newswire
Jul-18-19 07:35AM  Is Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay Fair? Simply Wall St.
Jul-10-19 05:53PM  Mirati Inks Deal with Novartis to Evaluate Tumor Candidate Zacks
04:41PM  How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug Investor's Business Daily
07:17AM  The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV Benzinga
Jul-09-19 04:30PM  Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155 PR Newswire
Jul-02-19 07:29AM  The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
Jul-01-19 04:30PM  Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors PR Newswire
Jun-30-19 08:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-27-19 04:05PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jun-25-19 08:30AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-24-19 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
09:43AM  Read This Before You Buy Any New Cancer Drug Stocks Motley Fool
Jun-18-19 07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-14-19 08:41AM  Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options Zacks
Jun-13-19 11:51AM  3 Under-the-Radar Stocks Trading at All-Time Highs Investopedia
Jun-12-19 10:03AM  Mirati Therapeutics, Inc. (NASDAQ:MRTX): Financial Strength Analysis Simply Wall St.
Jun-10-19 10:26AM  Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Jun-06-19 03:12PM  Mirati Therapeutics Could Soar Even Higher TheStreet.com
Jun-05-19 07:30AM  The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache Benzinga
Jun-04-19 03:18PM  The 10 Best Stocks for 2019 So Far InvestorPlace +9.90%
12:37PM  Amgens Good News on Lung Cancer Boosted Mirati Therapeutics. Heres What Wall Street Is Saying. Barrons.com
10:53AM  How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's? Benzinga
10:19AM  Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity Zacks
09:21AM  3 Cancer Stocks Given a Lift by Amgen Motley Fool
Jun-03-19 02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks +31.58%
12:47PM  Amgen Stock Jumps on Promising Cancer Drug Trial Results Barrons.com
12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool
May-31-19 01:04PM  What to watch at the world's largest cancer conference CNBC Videos
May-30-19 04:30PM  Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference PR Newswire
May-16-19 04:14PM  Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting Investor's Business Daily +11.13%
02:47PM  Here's Why Mirati Therapeutics Is Surging Today Motley Fool
10:47AM  What's Triggering The Rise In Mirati Shares? Benzinga
May-14-19 08:42AM  Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock Zacks
May-07-19 07:10AM  What You Must Know About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Beta Value Simply Wall St.
Apr-29-19 05:10PM  Mirati: 1Q Earnings Snapshot Associated Press
04:05PM  Mirati Therapeutics Reports First Quarter 2019 Financial Results PR Newswire
02:52PM  Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ? Insider Monkey
Apr-01-19 04:30PM  Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference PR Newswire
Mar-26-19 12:21PM  The Mirati Therapeutics (NASDAQ:MRTX) Share Price Has Gained 287%, So Why Not Pay It Some Attention? Simply Wall St.
Mar-05-19 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Feb-28-19 04:15PM  Mirati Therapeutics Reports Fourth Quarter Financial Results PR Newswire -5.02%
Feb-25-19 08:10AM  Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-19-19 04:15PM  Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors PR Newswire
Feb-07-19 04:30PM  Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day PR Newswire
Feb-04-19 05:01PM  Here's Why Mirati Therapeutics Jumped 55.8% in January Motley Fool
Jan-31-19 07:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics ACCESSWIRE
Jan-30-19 11:41AM  How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares? Simply Wall St. +5.31%
Jan-23-19 07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-22-19 04:01PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jan-17-19 08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga
Jan-16-19 08:45PM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
04:01PM  Mirati Therapeutics Announces Proposed Public Offering Of Common Stock PR Newswire
Jan-15-19 04:21PM  Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor PR Newswire
07:55AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics ACCESSWIRE
Jan-10-19 06:00AM  Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause ACCESSWIRE +13.27%
Jan-09-19 08:39AM  Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4% Zacks +5.46%
Jan-07-19 08:30AM  Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®) PR Newswire +7.31%
Jan-02-19 04:30PM  Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference PR Newswire +5.26%
Dec-20-18 04:42PM  Mirati Therapeutics Added To NASDAQ Biotechnology Index PR Newswire
Dec-12-18 03:27AM  Hedge Funds Are Buying Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Dec-10-18 04:15PM  Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors PR Newswire
Dec-04-18 07:20AM  Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar Discovering Underlying Factors of Influence GlobeNewswire
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAUM CHARLES MPresident & CEOFeb 04Option Exercise15.414,68772,247101,884Feb 06 04:41 PM
CHEN ISANEVP, Chief Medical OfficerJan 29Option Exercise24.993,00275,02039,401Jan 31 08:03 PM
Boxer Capital, LLC10% OwnerJan 10Buy97.5050,0004,875,0001,765,560Jan 14 04:30 PM
BAUM CHARLES MPresident & CEODec 24Option Exercise24.933187,92756,917Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Option Exercise5.446,66636,24613,326Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Sale125.006,666833,2509,159Dec 26 06:15 PM
CARTER BRUCE L ADirectorNov 20Option Exercise6.783,00020,3403,000Nov 22 04:46 PM
CARTER BRUCE L ADirectorNov 20Sale94.743,000284,2200Nov 22 04:46 PM
GREY MICHAEL GDirectorNov 12Option Exercise16.843,50058,9405,298Nov 14 06:30 PM
GREY MICHAEL GDirectorNov 12Sale102.443,042311,6222,256Nov 14 06:30 PM
BAUM CHARLES MPresident & CEOAug 22Option Exercise8.6752,368454,290117,851Aug 23 06:07 PM
BAUM CHARLES MPresident & CEOAug 22Sale86.2251,8104,467,31266,041Aug 23 06:07 PM
CARTER BRUCE L ADirectorAug 21Option Exercise6.783,00020,3403,000Aug 23 06:01 PM
CARTER BRUCE L ADirectorAug 21Sale89.243,000267,7200Aug 23 06:01 PM
GREY MICHAEL GDirectorAug 12Option Exercise16.843,50058,9404,840Aug 14 07:30 PM
GREY MICHAEL GDirectorAug 12Sale92.273,042280,6971,798Aug 14 07:30 PM
Avoro Capital Advisors LLC10% OwnerJul 23Sale101.8862,5006,367,5003,800,000Jul 25 04:33 PM
Boxer Capital, LLC10% OwnerJul 17Sale98.30725,00871,268,328990,560Jul 19 09:39 PM
CARTER BRUCE L ADirectorMay 22Option Exercise6.783,00020,3403,000May 24 05:00 PM
CARTER BRUCE L ADirectorMay 22Sale75.203,000225,5970May 24 05:00 PM
Donadio Jamie ASr. VP, CFOMay 16Option Exercise5.507,50041,2507,721May 20 07:00 PM
Donadio Jamie ASr. VP, CFOMay 16Sale75.007,500562,500221May 20 07:00 PM
GREY MICHAEL GDirectorMay 13Option Exercise16.847,100119,5647,100May 15 07:00 PM
GREY MICHAEL GDirectorMay 13Sale65.305,760376,1381,340May 15 07:00 PM
venBio Select Advisor LLC10% OwnerMar 20Sale72.8023,7811,731,2573,862,500Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 19Sale73.43100,0007,343,0003,886,281Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 18Sale76.55125,0009,568,7503,986,281Mar 20 04:05 PM
Braslyn Ltd.10% OwnerMar 01Option Exercise0.00275,0042753,135,970Mar 05 09:30 PM
Boxer Capital, LLC10% OwnerMar 01Option Exercise0.00425,0064251,715,566Mar 05 09:30 PM
Braslyn Ltd.10% OwnerMar 01Sale69.00275,00018,975,0002,860,966Mar 05 09:30 PM
Boxer Capital, LLC10% OwnerMar 01Sale69.00425,00029,325,0001,290,560Mar 05 09:30 PM